DIA Diagnostyka S.A.
Diagnostyka S.A. provides diagnostic services in Poland. The company operates as a medical laboratory, which offers services, such as ultrasound, X-ray, computed tomography, and magnetic resonance imaging. It also offers specialized research in the field of microbiology, autoimmunity, toxicology, and molecular biology, as well as human genome research, histopathological examinations, immunohistochemical tests, cytological tests, and cytogenetic tests. The company provides services to individual clients, and public and private entities. Diagnostyka S.A. was founded in 1998 and is headquartered in Kraków, Poland.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Diagnostyka (WSE: DIA)
›
Diagnostyka (WSE: DIA) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 8,645 employees.
The shares were at 148.80 PLN on 19 November 2026, down 17.9% over 52 weeks. Its 52-week range is 144.10 PLN to 208.00 PLN: the price is 28.5% below the high and 3.3% above the low.
At a market capitalisation of 5.02B PLN, it trades at 19.7 times trailing earnings and 15.3 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, a discount of 45% for DIA. It pays a dividend yielding 2.89% (it pays out 58% of its earnings), against a median of 0.73% among the dividend payers in that peer group.
Diagnostyka reports return on equity of 47.6%, an operating margin of 14.9% and revenue up 16.1% year over year.
Its debt exceeds its cash by 1.20B PLN, a debt-to-equity ratio of 2.05. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 7 analysts cover the stock; their mean price target of 191.39 PLN is 28.6% above the current price. The next earnings report is expected on 26 November 2026.